Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "bristol myers squibb"


Quest Diagnostics Introduces Dako's PD-L1 Complementary Diagnostic Test to Support Bristol-Myers Squibb's OPDIVO® Anti-PD-1 Therapy for Non-squamous Non-small Cell Lung Cancer

MADISON, N.J. , Oct. 9, 2015 /PRNewswire/ --Quest Diagnostics ( NYSE: DGX ), the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx ...
 SearchBug16 hours ago

Axion Biosystems Webinar Spotlights Simpler Approach to Measure...

Carol Marchetto, PhD - The Salk Institute for Biological Studies; John Graef, PhD - Bristol-Myers Squibb; Daniel Millard, PhD - Axion Biosystems Yorba Linda, CA (PRWEB) October 01, 2015 Progress in the wide-ranging discipline of ...
 PRWeb1 week ago
The World

Bristol's Opdivo boosts kidney cancer survival beyond 2 years

Bristol-Myers Squibb's immunotherapy drug Opdivo extended kidney cancer survival rates by more than two years in a late-stage trial, setting it up to be used beyond melanoma and lung cancer. The U.S. company said in July the study was stopped ...
 The World 247.com1 week ago Bristol-Myers Squibb says late stage trial for kidney cancer drug shows improved survival  Pharma Letter1 week ago Bristol-Myers kidney cancer drug boosts survival in study  Boston Globe2 weeks ago Opdivo: Bristol Drug Extends Survival Rate for Kidney Cancer Patients  WKRB News1 week ago

Telesta Gets FDA Date, Stellar To Be Uplisted To NASDAQ, BMY Inks Deal

Bristol-Myers Squibb Co. (BMY) and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology (I-O) target. BMY closed ...
 RTTNews.com1 month ago Bristol-Myers Squibb And QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration To Discover Novel Immuno-Oncology Antibodies  TheStreet.com1 month ago Bristol-Myers, QIMR to discover new immuno-oncology antibodies  Pharmaceutical Business Review1 month ago

Bristol-Myers Squibb And Pfizer Enroll First Patient In Phase 4 AUGUSTUS Trial To Evaluate Safety Of Eliquis (apixaban) In Nonvalvular Atrial Fibrillation Patients With A Recent Acute Coronary Syndrome Or Undergoing Percutaneous Coronary Intervention

Reddit Email Print Reprint Bristol-Myers Squibb Company and Pfizer Inc . today announced that the first patient has been enrolled into the Phase 4 clinical trial, AUGUSTUS. This two-by-two factorial, randomized controlled trial will ...
 TheStreet.com1 month ago First patient enrolled in Phase 4 AUGUSTUS trial of Eliquis  European Pharmaceutical Review1 month ago Phase 4 study assessing safety of Eliquis in high risk patients underway  TeleTrader.com1 month ago FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925  Sys-Con Media1 month ago
Pharmaceutical Technology

Bristol-Myers Squibb gains rights to acquire Promedior for about $1.25bn

Global biopharmaceutical company Bristol-Myers Squibb (BMS) has secured the exclusive rights to acquire US-based biotechnology firm Promedior and its fibrosis experimental drug PRM-151 for $1.25bn. PRM-151 is a recombinant form of human ...
 Pharmaceutical Technology1 month ago BMS gets exclusive rights to acquire Promedior  European Pharmaceutical Review1 month ago Bristol-Myers Squibb makes big pharma deals  Pharmafile1 month ago
Seeking Alpha

The Generation Portfolio: Wells Fargo, Disney, MFA Financial, Bristol-Myers Squibb

Sep. 1, 2015 9:04 AM ET | Includes: BMY, DIS, MFA, WFC by: Summary Last week provided some good buying opportunities, but they became fewer as the week went along. I used the market volatility to add Disney, Wells Fargo, Bristol-Myers ...
 Seeking Alpha1 month ago The Generation Portfolio: W.P. Carey, AT&T, Verizon And 3M Company  Seeking Alpha2 weeks ago
Irish Times

Bristol-Myers buys rights to fibrosis drug for up to $1.25bn

Drugmaker Bristol-Myers Squibb said it would buy the worldwide rights to a mid-stage fibrosis drug from privately held Promedior for up to $1.25 billion. Bristol-Myers said the deal, which includes a $150 million upfront payment, also gives it ...
 Irish Times1 month ago Bristol-Myers obtains rights to acquire drug developer Promedior for up to $1.25bn  Proactive Investors USA1 month ago Bristol-Myers Makes $150M Bet on Promedior, Fibrosis Drug  Xconomy1 month ago Bristol-Myers buys rights to acquire fibrosis drug developer: Reuters  ACQ Magazine1 month ago
Bidness Etc

Why Gilead Sciences, Inc. Can Easily Take Over Bristol-Myers Squibb Co

Gilead Sciences, Inc. ( NASDAQ:GILD ) has accumulated a lot of cash during its exceptional stint as leader of the hepatitis C drug market. The company is now being pressurized by investors and analysts to put its cash pile to strategic use, ...
 Bidness Etc1 month ago Stock Update: Gilead Sciences Inc (NASDAQ:GILD) Gilead combo drug fights all genotypes of hep C infection: data  Jutia Group2 weeks ago My Thoughts On Gilead Sciences' Capital Raise  Seeking Alpha3 weeks ago Gilead Sciences, Inc. Ready To Face Complera Patent War WIth Mylan  Bidness Etc4 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol myers squibb
Get updated on latest news & your favorite topics right in your inbox!
More     Less